Researchers reported a dual-engineering strategy for allogeneic CD19 CAR T cells designed to address both antigen escape and alloimmune rejection. The approach adds an anti-rejection CD70 CAR alongside the CD19 target, aiming to create a single cellular therapy that can better persist and maintain activity after infusion in the allogeneic setting. The report positions the work as an attempt to tackle two long-standing barriers that have constrained broader CAR T adoption—particularly for off-the-shelf development. If the safety and efficacy profile holds in follow-on studies, a rejection-control design using CD70 targeting could become a reusable blueprint for next-generation allogeneic CAR T constructs.